Abstract
A focused SAR study was conducted on a series of N1-substituted pyrazolopyrimidinone PDE2 inhibitors to reveal compounds with excellent potency and selectivity. The series was derived from previously identified internal leads and designed to enhance steric interactions with key amino acids in the PDE2 binding pocket. Compound 26 was identified as a lead compound with excellent PDE2 selectivity and good physicochemical properties.
Keywords:
PDE2; Pyrazolopyrimidinone; cAMP; cGMP.
Copyright © 2021 Elsevier Ltd. All rights reserved.
MeSH terms
-
Crystallography, X-Ray
-
Cyclic Nucleotide Phosphodiesterases, Type 2 / antagonists & inhibitors*
-
Cyclic Nucleotide Phosphodiesterases, Type 2 / metabolism
-
Dose-Response Relationship, Drug
-
Drug Discovery*
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Phosphodiesterase Inhibitors / chemical synthesis
-
Phosphodiesterase Inhibitors / chemistry
-
Phosphodiesterase Inhibitors / pharmacology*
-
Pyrazoles / chemical synthesis
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacology*
-
Pyrimidinones / chemical synthesis
-
Pyrimidinones / chemistry
-
Pyrimidinones / pharmacology*
-
Structure-Activity Relationship
Substances
-
Phosphodiesterase Inhibitors
-
Pyrazoles
-
Pyrimidinones
-
pyrazole
-
Cyclic Nucleotide Phosphodiesterases, Type 2
-
PDE2A protein, human